In short
Clinical trials investigating Autologous Chondrocytes are studying treatment for knee cartilage lesions. These studies look at whether the approach can improve symptoms, function, and quality of life compared with standard care. The main target group is adults with symptomatic articular cartilage damage in the knee.
Key points
- Clinical trials investigating Autologous Chondrocytes in the source data focus on knee cartilage damage. The study is a Phase 3 randomized controlled trial in patients with symptomatic articular cartilage lesions of the knee. It compares IMPACT with conservative treatment, which includes optional physical therapy and pain medication without surgery. The main outcomes are clinical improvement and quality of life measured at 3, 6, and 9 months. The trial uses KOOS and EQ5D to track these results. The study was completed and enrolled 60 patients.
Trial overview
The source data describe one randomized controlled trial that studied Autologous Chondrocytes in people with a symptomatic articular cartilage lesion of the knee. The trial compared IMPACT with conservative treatment and was completed.
Who was studied
The target population was patients with cartilage damage in the knee, especially lesions in the femoral condyles or trochlea. These are areas inside the knee joint where damaged cartilage can cause pain and problems with movement.
Treatment and comparison
The study tested IMPACT, given as an intra-articular injection, meaning an injection placed directly into the joint. The comparison group received conservative treatment, which in this trial meant optional physical therapy and pain medication, with no surgical treatment.
Study phase and design
This was a Phase 3 study with 60 enrolled participants. Phase 3 trials usually compare a treatment with standard care in a larger patient group to see how well it performs in real clinical use.
The study was designed to compare clinical improvement and quality of life after randomization. Randomization means patients are assigned to study groups by chance.
Outcomes measured
The main study outcomes were clinical improvement and quality of life at 3, 6, and 9 months. Clinical improvement means whether patients felt and functioned better after treatment.
The trial measured these outcomes using KOOS subscales and EQ5D. KOOS is a knee questionnaire, and EQ5D is a health and quality-of-life questionnaire.
What the results track
The study focused on whether Autologous Chondrocytes-related treatment could do better than standard care for symptoms and daily-life impact in knee cartilage lesions. The time points at 3, 6, and 9 months show that the researchers were looking at both short-term and medium-term results.